References
- Antman E, Hand M, Armstrong P, Bates E, Green L, Halasyamani L, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol. 2008; 51: 210–47
- Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998; 31: 967–72
- Hasin Y, Danchin N, Filippatos GS, Heras M, Janssens U, Leor J, et al. Recommendations for the structure, organization, and operation of intensive cardiac care units. Eur Heart J. 2005; 26: 1676–82
- Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: A two-year experience with 250 patients. Am J Cardiol. 1967; 20: 457–64
- Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993; 328: 673–9
- Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993; 328: 685–91
- Zijlstra F, Jan de Boer M, Moorntje JCA, Reiffer S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993; 328: 680–4
- Michels KB, Yusif S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995; 91: 476–85
- Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. JAMA 1997; 278: 2093–8
- Topol EJ, Burek K, O'Neill WW, Kewman DG, Kander NH, Shea MJ, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med. 1988; 318: 1083–8
- Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, et al. Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. J Am Coll Cardiol. 1996; 27: 625–32
- Ellis SG, Topol EJ, George BS, Kereiakes DJ, Debowey D, Sigmon KN, et al. Recurrent ischemia without warning: analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation 1989; 80: 1159–65
- Volpi A, de Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, et al. Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. J Am Coll Cardiol. 1994; 24: 608–15
- Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: A comparison of thrombolytic therapy and primary angioplasty. J Am Coll Cardiol. 1995; 26: 66–72
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20
- Grines CL. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty—the strategy of choice. N Engl J Med. 1996; 335: 1313–7